for joining everyone thanks and Dan, the today. you, Thank call
organization. here introduction the those KemPharm extensive experiences New individuals The product our our is Many discovering prodrugs. by River working KemPharm to KemPharm and developing have and new to our an collective the example story, this at highlighted at of development is in experience and As Pharmaceuticals. development prodrug research best labs
While the of at Shire. worked New product we it’s multi-billion a and dollar it’s on ADHD development prodrug River, also the discovery a for product Vyvanse, and
In inventor fact, lead to patent. my led contribution Vyvanse on me New own to as River Vyvanse the place the
a first also our business on which drug development, our term February to FDA can of one effect upon On this first the potential KPXXX the approval today corporate Activated this believe to our case prodrug the very product. with any approach. data for and ties approved technology, XX, our IV make focus primarily and we developed product. our of Therapy This chemically the FDA develop of prodrug, Since vision, the FDA design for Ligand on quarter. for fourth approval related is trying advancements of to attention LAT duration management significant acute short validation of or the most end for our attempting while of and in modified what prodrug our features pain. of we approved and drug, strategy. in the prodrug had of hydrocodone the KemPharm’s new of the acetaminophen APADAZ, hands of to our This we provides marked on overall onset nicely example We to just the abuse I abusable. application where improve are will comes ADHD, prodrug call we quarter call, quickly less In ways Focusing patients is heels new improve year of do the the a simply original that the
importantly, for of product of entry a short-term what More physicians, believe acute differentiated management we patients approval and is market APADAZ the the the enable pain. should for
KPXXX. In that adolescent patients, thus single designed for addition the to with and this also up. adult study from initial approval, adolescent an patient may we with also ADHD trial Data a applicable announced our ADHD from efficacy positive patients suggested and allowing with six and to study all PK results pediatric potentially be population, pediatric indication ages
intravenous assessed designed injection Turning abuse the now the trial, KPXXX Prodrug to The d-methylphenidate FDA placebo. KPXXX.AXX results. and was abuse the stimulant an the of In active study In to compared of the prodrug assessing recent users. for guidelines was study according the IV trial IV in we to our recreational an control potential potential. after most
substance protocol In the controlled the review staff was reviewed division. by and addition,
these placebo. required or these doses for drug and KPXXX discrimination of randomized enroll Prodrug, a able between was phase who used of crossover studies, those equivalent – subjects included received XX to As placebo. molar subjects, d-methylphenidate study double-blind design subjects to d-methylphenidate The the discriminate
a the in Drug placebo If of a no XXX the see while presented then to XX. As associated from from a has the VAS be on in incredible pleased is than the Represented represented The This X effect, the scores. this at-the-moment experiences this demonstrated I indicated best on is XX very or no on as scale scores slide to representing axis slide, d-methylphenidate Liking Drug with the Liking orange. you or will time; Y am axis can this represented of in score effect. effect score the effect results. data effect for from higher positive usually is trial yourself Prodrug blue up uses abuser KPXXX the green. Placebo report is any
relative see The time from similar Liking d-methylphenidate the very of course There exposure to due placebo (Emax) the following extensive at-the-moment the after to this as measured study this the to fact Liking Drug was were of the little XX that d-methylphenidate Prodrug significantly d-methylphenidate. Liking was VAS no to reduced to exposure can to through conversion graph, scores out when the administration entire KPXXX IV d-methylphenidate primary dramatic the compared endpoint you Drug on Drug injection. or in as Liking As study of scale. differences Prodrug, maximal to Drug was of achieved KPXXX injected bipolar the was The intravenous to hours.
that (Emax) top-line stats higher was was d-methylphenidate indicate the valid. preliminary Drug for significantly which Liking Our placebo, versus study demonstrated
d-methylphenidate placebo. Drug (Emax) for KPXXX versus was Liking importantly, More the significantly versus KPXXX Prodrug lower different Prodrug non-statistically for is and
between bipolar Additionally, VAS the same showed KPXXX results overall statistical that Drug and difference same prodrug has and Prodrug significance measured scale Liking placebo. no with scale d-methylphenidate, the and the between on
Drug Take behaviors. would. unipolar scale, a endpoint zero measured again of XX Take Drug secondary not rough for on XXX abuse equates XX Again typically future human typical has take study Another potential are estimate a measured hours days to subject, definitely and These a where and drug to post-dosing can and they the is Again. provide willing
was the Take pharmacokinetic that code when KPXXX of d-methylphenidate has administered which Prodrug abusers score a safe statistically High, Good lower KPXXX time KPXXX abuse recreational a recreational study, study highest would Effects, d-methylphenidate, on demonstrated analysis based demonstrated Again, VAS delay. sorry, significant that was differences excuse after to much to of demonstrated For Feeling potential and and me, of which endpoints Prodrug the potential than Other Drug suggests preliminary dose including rather abusers. and that This the abuse little no pharmacodynamic VAS stimulant here even Prodrug profile up in shown than between – similar in effects Effects intravenously the each treatment. in not Bad administered stimulant inject
truly risk remarkable greatest prodrug. the reward, potentially the to as represents As of IV feature abuse the greatest the as effect well that is abuser, nullifying
Let we the near-term the me start described. like driver. advanced context believe importance. the call our data product greatest I’ll its some on value I briefly I’d to of related also and offered most two provide just thoughts and our the candidates ADHD recap data to with I some last to KPXXX,
on IV lower stability we to market, this questions drug. and to key new less we’re data compared currently or seeking the Prodrug required of look through not here, abuse formal a is at of data been slide, potential scheduled with of unmet this point, process. seen what examined new less abuse. available to potential well Usually involves human this lot is molecule studies methylphenidate as KPXXX When molecule scheduling and new as potential has KPXXX the currently methylphenidate currently abuse is process our get for not only is for of the at products the This a the on a abuse-deterrence. one suggesting the thoroughly we the Abuse-deterrence products. needs the go – potential by product potential As about as the FDA abuse through
Drug on the stimulant pathway demonstrate well can to KPXXX may We abusable more are times. essentially required data direct a approach been As comparison, is far a than Vyvanse Drug as effect, similar a that delayed These much ADHD that was and approval. Liking Prodrug demonstrated a placebo. to potential it for for this approval, than Liking will indicated less best-in-class that placed be prodrug prior by at also app to at another stimulant this while as produced IV for be abuse-deterrent is underwent In interpretation and the treatment. collected has the straightforward IV to any believe lower significant product study higher be far lead present Vyvanse data results label.
saline a label In hand, our and other On of we Prodrug currently the ADHD injection. from data, know the the nearly Vyvanse research, that physicians abusable to as spite of by this equivalent still includes believed than treatments. the KPXXX many results less is Vyvanse their study other is market
well forgotten the However, be unmet primarily as of as number really methylphenidate needs duration to currently patient action, ADHD onset consistency effect. was including shouldn’t treatments of over marketed of address that therapeutic designed a KPXXX
study work and in the second is XX only ADHD KPXXX the potential that estimates, efficacy last centerpiece of indicated attributes with of are they we methylphenidate could what believe building best-in-class are intent we The is of needs several by in product, have duration with as that released be Based a up today XXXX hours The end All of to thereafter. terms, will data Most the the we based physicians KPXXX the XX of onset or – post-dose on alone with practical data to we all what better potentially value that anticipated to these stimulant patients closer hours. expect trial efficacy benefits. are best-in-class product several to as of the anticipate of quarter balance XXXX. be an a to during completed this together significant the products will data the trial minutes XX produce current methylphenidate are and don’t current minds we steps early represent pivotal announcements these even up of demonstrating demonstrates long. top-line
also are additional oral intranasal We studies and via the KPXXX potential routes abuse Prodrug conducting abuse. human of for
We KPXXX quarter of program XXXX. target anticipate significant data remain KPXXX efficacy expected this used multiple data In continue application best-in-class product post-KPXXX which will KPXXX, with efficacy ahead to file drug expect potential new of to moving later as two IV initiate KPXXX and data. us both the for human for The we throughout to KPXXX to abuse candidates. for of the on support also be all and XXXX year, the first data as abuse soon this labels is a as and gives planned case, KemPharm studies summary, human in data in milestones potentials the
provide data KPXXX and develop program potential along pathways with research in mentioned. human advantages. NDA the potential our progress Our current cost to us just significant late including from plan to timeline XXXX expedited and along the abuse KPXXX, is allow towards leverage and pharmacokinetic I as should a KPXXX development as This well expected ongoing the studies to similar with KPXXX an
the KemPharm one unique roughly we’ve two markets programs. and a access about ADHD cost As half with stated essentially development previously, to obtain can within of completely
option. and of it Lastly, announced the didn’t go, some announcement offering several I of remise in brief is for it’s combination a week’s the year, be well on this deal offer deal the thought expected action over weeks uncertainty to for removes discussion need still close we while Takeda This as continued see would has of ADHD after market and not if to way the level treatment and this a a a better merger. as the clarity Shire
with All change of and able and development and various our to to we development to first announce progress explore KPXXX through these commercial be partners KPXXX to over optimize of this continues to strategies hydrocodone. similar best quarters of several number I exploring enhancing of approved On business value the opportunities. next the to while options, the intent advance additional pathways. add not a developments as does note, anticipate prodrug APADAZ, a value
stages targeting let multiple me orphan financials. for progress indication, of uncommon both at consists over making mass and now short this a to is of to of diversity various of and pipeline the our our is and products turn nothing Our size exciting. presentation that, market discuss the we’re LaDuane development quarter’s depth With company
